$695 | Single User
$1395 | Global License

Physician Views - Breathing new life into patient care; patient-centric services in the respiratory market
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 08 Apr 2014 | 113 | In Stock
Related Topics: GlaxoSmithKline

Introduction

Scope



According to the Institute of Medicine, patient-centric care can be defined as "providing care that is respectful of and responsive to individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions."


In a 2012 article published in the NEJM, Charles Bardes suggested that "as a rhetorical slogan, it (patient-centric medicine) stakes a position in contrast to which everything else is both doctor-centred and suspect on ethical, economic, organisational and metaphoric grounds."


Likening a hypothetical patient to a "shuttlecock" – who is assessed and subsequently transferred to another physician on multiple occasions – patient-centricity "seeks to focus medical attention on the individual patient's needs and concerns, rather than the doctor's," adds Bardes.


Patient-centricity has also gained significant momentum from a commercial perspective. This has been partly driven by a broad move towards more personalised healthcare offerings, alongside a greater requirement for industry to demonstrate and communicate the 'value proposition' of newly developed drugs. Furthermore, the consumer base – as befits the evolution of the patient/physician relationship described above – has become increasingly engaged and empowered.


With respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) known to be under-diagnosed, frequently mistreated and heavily linked to patient non-adherence issues, they are identified as exerting a significant burden on healthcare systems and the broader social-economic landscape. As such, they are an important focal point for the growing patient-centric narrative.


Furthermore, GlaxoSmithKline's ongoing (and much discussed) Salford Lung study – which is designed to demonstrate that improved outcomes may stem from better adherence (the study is assessing the company's once-daily ICS/LABA combination Breo Ellipta) – encompasses both the concepts of patient-centricity and real-world data.


With the Salford Lung study touching on how effective support of patients in the community can result in better outcomes and the generation of high quality data that can be submitted to regulators, FirstWord is polling pulmonologists based in the US and EU5 to assess how physicians perceive patient-centric support services.


Puchase Reasons


Specifically, FirstWord is asking pulmonologists...


  • To detail their knowledge and awareness of patient-centric support services made available to patients suffering from asthma and/or COPD?

  • To identify the key reasons for recommending patient-centric support programmes to asthma/COPD patients?

  • For what reasons they would not recommend patient-centric support programmes to asthma/COPD patients?

  • at they believe is the primary offering of patient-centric support programmes for asthma/COPD patients?

  • What feedback they have received from patients with regard to these programmes?
  • Table of Contents
    for Physician Views - Breathing new life into patient care; patient-centric services in the respiratory market [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    113 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views - Breathing new life into patient care; patient-centric services in the respiratory market [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...